{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:39:36Z","timestamp":1787614776395,"version":"build-2736575974"},"reference-count":64,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Hodgkin\u2019s lymphoma is a rare yet highly curable disease in the majority of patients treated with modern chemotherapy regimens. For patients who fail to respond to or relapse after initial systemic therapies, treatment with high-dose chemotherapy and autologous hematopoietic stem cell transplantation can provide a cure for many with chemotherapy-responsive lymphoma. Patients who relapse after autologous transplant or those with chemorefractory disease have poor prognosis and represent a high unmet need. Allogeneic hematopoietic stem cell transplantation provides a proven curative therapy for these patients and should be considered, especially in young and medically fit patients. The use of newer agents in this disease such as brentuximab vedotin and immune checkpoint inhibitors can help bring more patients to transplantation and should be considered as well.<\/jats:p>","DOI":"10.3390\/jpm12020125","type":"journal-article","created":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T08:09:20Z","timestamp":1642493360000},"page":"125","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Reappraising the Role of Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed and Refractory Hodgkin\u2019s Lymphoma: Recent Advances and Outcomes"],"prefix":"10.3390","volume":"12","author":[{"given":"Taha","family":"Al-Juhaishi","sequence":"first","affiliation":[{"name":"Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK 73104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5093-1634","authenticated-orcid":false,"given":"Azra","family":"Borogovac","sequence":"additional","affiliation":[{"name":"Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK 73104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Ibrahimi","sequence":"additional","affiliation":[{"name":"Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK 73104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Wieduwilt","sequence":"additional","affiliation":[{"name":"Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK 73104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7302-8299","authenticated-orcid":false,"given":"Sairah","family":"Ahmed","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center, University of Texas, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/bjh.15614","article-title":"Diagnosis of Hodgkin lymphoma in the modern era","volume":"184","author":"Wang","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/ajh.25071","article-title":"Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management","volume":"93","author":"Ansell","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s11899-011-0091-0","article-title":"The role of autologous transplantation in Hodgkin lymphoma","volume":"6","author":"Engert","year":"2011","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1182\/blood.V81.5.1137.1137","article-title":"The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin\u2019s disease. A single-center eight-year study of 155 patients","volume":"81","author":"Chopra","year":"1993","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: A randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41572-020-0189-6","article-title":"Hodgkin lymphoma","volume":"6","author":"Connors","year":"2020","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"6445","DOI":"10.1158\/0008-5472.CAN-16-1311","article-title":"Allogeneic stem cell transplantation: A historical and scientific overview","volume":"76","author":"Singh","year":"2016","journal-title":"Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.bmt.1705008","article-title":"The graft-versus-lymphoma effect: Clinical review and future opportunities","volume":"36","author":"Butcher","year":"2005","journal-title":"Bone Marrow Transpl."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1182\/blood-2017-09-772673","article-title":"Transplant strategies in relapsed\/refractory Hodgkin lymphoma","volume":"131","author":"Shah","year":"2018","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/bjh.15685","article-title":"Impact of graft-versus-lymphoma effect on outcomes after reduced intensity conditioned-alemtuzumab allogeneic haematopoietic stem cell transplantation for patients with mature lymphoid malignancies","volume":"184","author":"Brierley","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.bbmt.2015.02.022","article-title":"Role of Cytotoxic Therapy with Hematopoietic Cell Transplantation in the Treatment of Hodgkin Lymphoma: Guidelines from the American Society for Blood and Marrow Transplantation","volume":"21","author":"Perales","year":"2015","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3322\/caac.21438","article-title":"Hodgkin lymphoma: A review and update on recent progress","volume":"68","author":"Shanbhag","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s11899-017-0382-1","article-title":"A Review of Autologous Stem Cell Transplantation in Lymphoma","volume":"12","author":"Zahid","year":"2017","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_14","first-page":"467","article-title":"Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin\u2019s disease in relapse or failure after initial chemotherapy: Results of the Groupe d\u2019\u00c9tudes des Lymphomes de l\u2019Adulte H89 trial","volume":"20","author":"Mounier","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_15","first-page":"CD009411","article-title":"High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed\/refractory Hodgkin lymphoma","volume":"6","author":"Rancea","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/j.bbmt.2013.09.018","article-title":"Simplified Validated Prognostic Model for Progression-Free Survival after Autologous Transplantation for Hodgkin Lymphoma","volume":"19","author":"Hahn","year":"2013","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_17","first-page":"221","article-title":"New Prognostic Score Based on Treatment Outcome of Patients With Relapsed Hodgkin\u2019s Lymphoma Registered in the Database of the German Hodgkin\u2019s Lymphoma Study Group","volume":"20","author":"Josting","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/sj.bmt.1704789","article-title":"A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin\u2019s disease","volume":"35","author":"Hahn","year":"2005","journal-title":"Bone Marrow Transpl."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/sj.bmt.1702796","article-title":"Autotransplants for Hodgkin\u2019s disease in first relapse or second remission: A report from the autologous blood and marrow transplant registry (ABMTR)","volume":"27","author":"Lazarus","year":"2001","journal-title":"Bone Marrow Transpl."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/annonc\/mdi119","article-title":"Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin\u2019s lymphoma autografted after a first relapse","volume":"16","author":"Sureda","year":"2005","journal-title":"Ann. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2018-07-861641","article-title":"Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse","volume":"132","author":"Moskowitz","year":"2018","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","article-title":"Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma","volume":"128","author":"Chen","year":"2016","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood-2020-136384","article-title":"Consolidation with Nivolumab and Brentuximab Vedotin after Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma","volume":"136","author":"Herrera","year":"2020","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/sj.bmt.1704214","article-title":"Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin\u2019s disease or aggressive non-Hodgkin\u2019s lymphoma","volume":"32","author":"Kewalramani","year":"2003","journal-title":"Bone Marrow Transpl."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.3109\/10428194.2013.798868","article-title":"Defining a hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant","volume":"54","author":"Arai","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.hoc.2014.08.011","article-title":"Stem cell transplantation in Hodgkin lymphoma","volume":"28","author":"Reddy","year":"2014","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1016\/S0140-6736(05)66659-7","article-title":"Clinical evidence of a graft-versus-Hodgkin\u2019s-lymphoma effect after reduced-intensity allogeneic transplantation","volume":"365","author":"Peggs","year":"2005","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.bbmt.2007.12.496","article-title":"Evidence of a Graft-versus-Hodgkin Lymphoma Effect in the Setting of Extensive Bone Marrow Involvement","volume":"14","author":"Anderlini","year":"2008","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1016\/j.bbmt.2015.05.010","article-title":"The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen","volume":"21","author":"Pavletic","year":"2015","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s11864-014-0287-3","article-title":"The role of allogeneic stem cell transplantation in Hodgkin\u2019s lymphoma","volume":"15","author":"Sureda","year":"2014","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1182\/bloodadvances.2017011130","article-title":"Should all patients with HL who relapse after ASCT be considered for allogeneic SCT? A consult, yes; A transplant, not necessarily","volume":"2","author":"Moskowitz","year":"2018","journal-title":"Blood Adv."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1182\/bloodadvances.2017011122","article-title":"Should all patients with Hodgkin lymphoma who relapse after autologous SCT be considered for allogeneic SCT?","volume":"2","author":"Peggs","year":"2018","journal-title":"Blood Adv."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3324\/haematol.2011.045757","article-title":"Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin\u2019s lymphoma. Results of the HDR-ALLO study\u2013A prospective clinical trial by the Grupo Espa\u00f1ol de Linfomas\/ Trasplante de M\u00e9dula Osea","volume":"97","author":"Sureda","year":"2012","journal-title":"Haematologica"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1200\/JCO.2007.13.2415","article-title":"Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin\u2019s lymphoma: An analysis from the lymphoma working party of the European Group for Blood and Marrow Transplantation","volume":"26","author":"Sureda","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3324\/haematol.11828","article-title":"Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin\u2019s lymphoma: The updated M.D. Anderson Cancer Center experience","volume":"93","author":"Anderlini","year":"2008","journal-title":"Haematologica"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3324\/haematol.13441","article-title":"Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin\u2019s lymphoma: Identification of prognostic factors predicting outcome","volume":"94","author":"Robinson","year":"2009","journal-title":"Haematologica"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.bbmt.2008.11.011","article-title":"Unrelated Donor Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma","volume":"15","author":"Devetten","year":"2009","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.3324\/haematol.2012.080895","article-title":"Impact of disease status and stem cell source on the results of reduced intensity conditioning transplant for Hodgkin\u2019s lymphoma: A retrospective study from the French Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)","volume":"98","author":"Marcais","year":"2013","journal-title":"Haematologica"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/ajh.23897","article-title":"The role of hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma","volume":"90","author":"Kako","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1182\/blood-2009-12-253856","article-title":"Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: A retrospective study based on the time of HLA typing and donor availability","volume":"115","author":"Sarina","year":"2010","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.bbmt.2008.08.014","article-title":"Comparison of Outcomes of HLA-Matched Related, Unrelated, or HLA-Haploidentical Related Hematopoietic Cell Transplantation following Nonmyeloablative Conditioning for Relapsed or Refractory Hodgkin Lymphoma","volume":"14","author":"Burroughs","year":"2008","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1182\/blood-2004-01-0231","article-title":"Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: A report of the International Bone Marrow Transplant Registry","volume":"104","author":"Freytes","year":"2004","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/nrclinonc.2015.128","article-title":"Modern approaches to HLA-haploidentical blood or marrow transplantation","volume":"13","author":"Kanakry","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1182\/blood-2015-04-639831","article-title":"Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia","volume":"126","author":"Ciurea","year":"2015","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1016\/j.bbmt.2018.07.019","article-title":"Outcomes of Advanced Hodgkin Lymphoma after Umbilical Cord Blood Transplantation: A Eurocord and EBMT Lymphoma and Cellular Therapy & Immunobiology Working Party Study","volume":"24","author":"Paviglianiti","year":"2018","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1200\/JCO.2006.06.9914","article-title":"Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation","volume":"24","author":"Baron","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1053\/bbmt.2003.50014","article-title":"Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant","volume":"9","author":"Feinstein","year":"2003","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3109\/10428194.2013.802780","article-title":"Unrelated and alternative donor allogeneic stem cell transplant in patients with relapsed or refractory Hodgkin lymphoma: A systematic review","volume":"55","author":"Messer","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1200\/JCO.2017.72.6869","article-title":"Post-transplantation cyclophosphamide-based haploidentical transplantation as alternative to matched sibling or unrelated donor transplantation for hodgkin lymphoma: A registry study of the lymphoma working party of the european society for blood and marr","volume":"35","author":"Gayoso","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.bbmt.2019.05.025","article-title":"Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide\u2013Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma","volume":"25","author":"Ahmed","year":"2019","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41409-020-0989-z","article-title":"Can we cure refractory Hodgkin\u2019s lymphoma with transplantation?","volume":"56","author":"Ciurea","year":"2021","journal-title":"Bone Marrow Transpl."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.semcancer.2019.08.001","article-title":"Immune-checkpoint inhibitors for the treatment of metastatic melanoma: A model of cancer immunotherapy","volume":"59","author":"Queirolo","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1093\/annonc\/mdx151","article-title":"Immune checkpoint inhibitors in advanced renal cell carcinoma: Experience to date and future directions","volume":"28","author":"Atkins","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1158\/1078-0432.CCR-18-1538","article-title":"Immunotherapy in non-small cell lung cancer: Facts and hopes","volume":"25","author":"Doroshow","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Meti, N., Esfahani, K., and Johnson, N.A. (2018). The role of immune checkpoint inhibitors in classical hodgkin lymphoma. Cancers, 10.","DOI":"10.3390\/cancers10060204"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1182\/blood-2016-09-738385","article-title":"Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed\/refractory lymphoma","volume":"129","author":"Merryman","year":"2017","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1182\/blood-2017-01-761346","article-title":"PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: High response rate but frequent GVHD","volume":"130","author":"Haverkos","year":"2017","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1182\/blood-2016-11-749556","article-title":"Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma","volume":"129","author":"Herbaux","year":"2017","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/ejh.13186","article-title":"Allogeneic hematopoietic stem cell transplantation in r\/r Hodgkin lymphoma after treatment with checkpoint inhibitors: Feasibility and safety","volume":"102","author":"Dada","year":"2019","journal-title":"Eur. J. Haematol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.bbmt.2018.08.028","article-title":"Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic Transplantation","volume":"25","author":"Ijaz","year":"2019","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1038\/s41375-021-01193-6","article-title":"Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma","volume":"35","author":"Merryman","year":"2021","journal-title":"Leukemia"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1158\/1078-0432.CCR-21-0164","article-title":"Combining AFM13, a bispecific CD30\/CD16 antibody, with cytokine-activated blood and cord blood\u2013derived NK cells facilitates CAR-like responses against CD30+ malignancies","volume":"27","author":"Kerbauy","year":"2021","journal-title":"Clin. Cancer Res."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/12\/2\/125\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:03:14Z","timestamp":1760133794000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/12\/2\/125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,18]]},"references-count":64,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["jpm12020125"],"URL":"https:\/\/doi.org\/10.3390\/jpm12020125","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,18]]}}}